EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY 4.0

Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions

Takuto Hara, Hanako Nishimoto, Tomoaki Terakawa, Yasuyoshi Okamura, Yukari Bando, Hideto Ueki, Kotaro Suzuki, Yoji Hyodo, Jun Teishima, Koji Chiba, Ryosuke Kuroda, Hideaki Miyake

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02711-7 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Takuto Hara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Kobe, 650-0017, Japan. supermarimo85@gmail.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bone Density, Bone Neoplasms, Androgen Antagonists. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kobe University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases.

Methods

A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year.

Results

Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups ( P < 0.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups ( P < 0.001). However, no significant interaction was observed between group classification and time ( P = 0.817).

Conclusion

The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBone DensityBone NeoplasmsAndrogen AntagonistsHumansMaleAgedMiddle AgedLongitudinal StudiesAbsorptiometry, PhotonAged, 80 and overLumbar VertebraeFemur NeckAnilidesNitrilesTosyl Compounds

Stichwörter der Autor:innen

Androgen deprivation therapyAndrogen-receptor signaling inhibitorsBone mineral densityProstate cancer

Substanzen

Androgen AntagonistsbicalutamideAnilidesNitrilesTosyl Compounds

Autor:innen und Institutionen

  • Department of Urology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Kobe, 650-0017, Japan. supermarimo85@gmail.com.
  • Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Urology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Kobe, 650-0017, Japan.

Förderung

  • Kobe University

Zitieren

APA

Hara, T., Nishimoto, H., Terakawa, T., Okamura, Y., Bando, Y., Ueki, H., Suzuki, K., Hyodo, Y., Teishima, J., Chiba, K., Kuroda, R., & Miyake, H. (2025). Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02711-7

Vancouver

Hara T, Nishimoto H, Terakawa T, Okamura Y, Bando Y, Ueki H, et al. Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02711-7

BibTeX
@article{Hara2025,
  author = {Hara, Takuto and Nishimoto, Hanako and Terakawa, Tomoaki and Okamura, Yasuyoshi and Bando, Yukari and Ueki, Hideto and Suzuki, Kotaro and Hyodo, Yoji and Teishima, Jun and Chiba, Koji and Kuroda, Ryosuke and Miyake, Hideaki},
  title = {Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02711-7}
}
Kostenlos starten →